CMIAD principal investigator modifies Botox treatment for the relief of pain
Scientists have manufactured a new bio-therapeutic molecule that could be used to treat neurological disorders such as chronic pain and epilepsy.
A team of 22 scientists from 11 research institutes, led by Professor Bazbek Davletov (now at the University of Sheffield) created and characterised a new molecule that was able to alleviate hypersensitivity to inflammatory pain.
The work is featured on the cover of the October 2013 issue of the scientific journal Bioconjugate Chemistry.
Professor Bazbek Davletov joined the Department of Biomedical Science in September last year from the Medical Research Council’s Laboratory of Molecular Biology in Cambridge, where his team developed a new way of joining and rebuilding molecules.
By using elements of Clostridium botulinum and Clostridium tetani neurotoxins, commonly known as Botox and tetanus toxin respectively, the scientists were able to develop a molecule with new biomedical properties, without unwanted toxic effects.
We hope that the engineered molecule could improve the quality of life for those people who suffer from chronic pain
Professor Bazbek Davletov
While the Botox element is able to block neuronal communication – and therefore pain signals - for months, the tetanus component targets the central nervous system very effectively.
The combination of the two elements is of great interest for neuroscience and can be applied to the treatment of several neurological disorders, particularly chronic pain conditions and epilepsy.
Botox and tetanus neurotoxins hold great promise for clinical applications, but their paralytic activity was a stumbling block until now. The team demonstrated that their newly engineered molecule is a potent non-paralysing neuronal blocker.
Preclinical collaborative studies with Dr Enrico Ferrari at the University of Lincoln and Professor Stephen Hunt at University College London indicate usefulness of the new molecule for the alleviation of inflammatory pain.
Professor Davletov added: “Currently painkillers relieve lingering pain only temporarily and often have unwanted side effects. A single injection of the new molecule at the site of pain could potentially relieve pain for many months in humans and this now needs to be tested.
“We hope that the engineered molecule could improve the quality of life for those people who suffer from chronic pain. We are now negotiating transfer of the technology to a major pharmaceutical company.”
Professor Davletov’s team in the Department of Biomedical Science is now working not only on neuronal blockers tailored for various neurological conditions but also on developing new cancer drugs.
Paper reference: Synthetic Self-Assembling Clostridial Chimera for Modulation of Sensory Functions Bioconjugate Chemistry, DOI: 10.1021/bc4003103
Clare Parkin, Media Relations Officer
+44 114 222 9851
Centre for Membrane Interactions and Dynamics
Bringing cell biologists, physical scientists, computational biologists and clinicians together, with the ultimate aim of developing improved therapies.
Research Excellence Framework 2021 results
The results demonstrate our research and impact excellence across a broad range of disciplines and confirm that our research is having a significant positive impact on lives across the globe.